ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Efficacy of Single-Strength Trimethoprim-Sulfamethoxazole Thrice Weekly for Pneumocysitis Jirovecii Pneumonia Prophylaxis Post Liver Transplantation

A. Puing, A. Subramanian

Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA

Meeting: 2020 American Transplant Congress

Abstract number: D-151

Keywords: Infection, Liver, Prophylaxis

Session Information

Session Name: Poster Session D: All Infections (Excluding Kidney & Viral Hepatitis)

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Current guidelines recommend Pneumocystis jirovecii pneumonia (PJP) prophylaxis for at least 6-12 months after liver transplant (LTx) with preferably Trimethoprim-sulfamethoxazole (TMP-SMX) at a daily dose of 80/400 mg (single-strength) or 160/800 mg (double-strength) three times weekly. Here we aimed to retrospectively examine our institutional experience using a lower dose, single-strength TMP-SMX thrice weekly for 12 months postLTx for PJP prophylaxis from 2012 to 2016.

*Methods: Retrospective cohort study of adult patients that underwent LTx at our institution from 01/2012-12/2016 and were discharged on PJP prophylaxis. Patients were followed for a year post-LTx. Baseline demographic, clinical, serological, and outcomes information were collected.

*Results: 260 LTx recipients met inclusion criteria. 248 (93.8%) of these patients were initially prescribed single-strength TMP-SMX for prophylaxis. 12 (6.2%) were prescribed alternative prophylaxis because of sulfa allergy. Of those receiving single-strength TMP-SMX, 228 (91.9%) took it thrice a week, 18 (7.3%) twice a week, and 2 (0.8%) daily. Patient characteristics are shown in Table 1. 88 (35.5%) patients discontinued TMP-SMX because of adverse effects. The most common reasons for TMP-SMX discontinuation or avoidance was development of cytopenia in 38 (43.2%) and elevated creatinine in 30 (34.1%) (Table 2). Of the 260 adult liver transplant recipients transplanted at our institution over a 5-year period ending in 12/2016, only 1 opportunistic infection (OI) was documented in the 1st-year post-LTx, namely toxoplasmosis in a patient 4 months post-LTx for hepatocellular carcinoma.

*Conclusions: This study shows that low-dose TMP-SMX thrice a week is relatively effective in preventing OI in LTx recipients during the first-year post-transplant. Cytopenia and elevated creatinine are relatively common in the postoperative period and may be multifactorial; when cytopenia or renal insufficiency improve, patients should be rechallenged with TMP-SMX. Further research is needed to clarify the optimal dosing of TMP-SMX to prevent PJP and other OIs while avoiding adverse drug reactions.

 border=

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Puing A, Subramanian A. Efficacy of Single-Strength Trimethoprim-Sulfamethoxazole Thrice Weekly for Pneumocysitis Jirovecii Pneumonia Prophylaxis Post Liver Transplantation [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/efficacy-of-single-strength-trimethoprim-sulfamethoxazole-thrice-weekly-for-pneumocysitis-jirovecii-pneumonia-prophylaxis-post-liver-transplantation/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences